Literature DB >> 25757463

Toll-like receptor 5 deficiency exacerbates cardiac injury and inflammation induced by myocardial ischaemia-reperfusion in the mouse.

Roumen Parapanov1, Jérôme Lugrin1, Nathalie Rosenblatt-Velin2, François Feihl2, Bernard Waeber2, Giuseppina Milano3, Catherine Vergely4, Na Li4, Pal Pacher5, Lucas Liaudet1.   

Abstract

Myocardial ischaemia-reperfusion (MIR) triggers a sterile inflammatory response important for myocardial healing, but which may also contribute to adverse ventricular remodelling. Such inflammation is initiated by molecular danger signals released by damaged myocardium, which induce innate immune responses by activating toll-like receptors (TLRs). Detrimental roles have been recently reported for TLR2, TLR3 and TLR4. The role of other TLRs is unknown. We therefore evaluated the role of TLR5, expressed at high level in the heart, in the development of myocardial damage and inflammation acutely triggered by MIR. TLR5(-/-) and wild-type (WT) mice were exposed to MIR (30 min ischaemia, 2 h reperfusion). We measured infarct size, markers of cardiac oxidative stress, myocardial phosphorylation state of mitogen-activated protein (MAP) kinases and AKT, expression levels of chemokines and cytokines in the heart and plasma, as well as cardiac function by echography and conductance volumetry. TLR5-deficient mice had normal cardiac morphology and function under physiological conditions. After MIR, the absence of TLR5 promoted an increase in infarct size and myocardial oxidative stress. Lack of TLR5 fostered p38 phosphorylation, reduced AKT phosphorylation and markedly increased the expression of inflammatory cytokines, whereas it precipitated acute LV (left ventricle) dysfunction. Therefore, contrary to the detrimental roles of TLR2, TLR3 and TLR4 in the infarcted heart, TLR5 is important to limit myocardial damage, inflammation and functional compromise after MIR.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25757463     DOI: 10.1042/CS20140444

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  5 in total

Review 1.  The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis.

Authors:  Sumanth D Prabhu; Nikolaos G Frangogiannis
Journal:  Circ Res       Date:  2016-06-24       Impact factor: 17.367

2.  Leukocyte TLR5 deficiency inhibits atherosclerosis by reduced macrophage recruitment and defective T-cell responsiveness.

Authors:  Guilielmus H J M Ellenbroek; Gijs H M van Puijvelde; Adam A Anas; Martine Bot; Miriam Asbach; Arjan Schoneveld; Peter J van Santbrink; Amanda C Foks; Leo Timmers; Pieter A Doevendans; Gerard Pasterkamp; Imo E Hoefer; Tom van der Poll; Johan Kuiper; Saskia C A de Jager
Journal:  Sci Rep       Date:  2017-02-16       Impact factor: 4.379

3.  TLR5 participates in the TLR4 receptor complex and promotes MyD88-dependent signaling in environmental lung injury.

Authors:  Salik Hussain; Collin G Johnson; Joseph Sciurba; Xianglin Meng; Vandy P Stober; Caini Liu; Jaime M Cyphert-Daly; Katarzyna Bulek; Wen Qian; Alma Solis; Yosuke Sakamachi; Carol S Trempus; Jim J Aloor; Kym M Gowdy; W Michael Foster; John W Hollingsworth; Robert M Tighe; Xiaoxia Li; Michael B Fessler; Stavros Garantziotis
Journal:  Elife       Date:  2020-01-28       Impact factor: 8.140

Review 4.  Damage-Associated Molecular Patterns in Myocardial Infarction and Heart Transplantation: The Road to Translational Success.

Authors:  Max J M Silvis; Selma E Kaffka Genaamd Dengler; Clémence A Odille; Mudit Mishra; Niels P van der Kaaij; Pieter A Doevendans; Joost P G Sluijter; Dominique P V de Kleijn; Saskia C A de Jager; Lena Bosch; Gerardus P J van Hout
Journal:  Front Immunol       Date:  2020-12-08       Impact factor: 7.561

5.  Toll-like receptor 5 deficiency diminishes doxorubicin-induced acute cardiotoxicity in mice.

Authors:  Zhen-Guo Ma; Chun-Yan Kong; Hai-Ming Wu; Peng Song; Xin Zhang; Yu-Pei Yuan; Wei Deng; Qi-Zhu Tang
Journal:  Theranostics       Date:  2020-09-02       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.